Misuse of Drugs (Amendment) Bill and Constitution of the Republic of Singapore (Amendment) Bill Tabled in Parliament to Introduce New Legislative Framework for Psychoactive Substances

On 24 February 2023, the Misuse of Drugs (Amendment) Bill (“MDA Bill“) and the Constitution of the Republic of Singapore (Amendment) Bill were introduced for First Reading in Parliament.  The proposed amendments to the Misuse of Drugs Act 1973 (“MDA“) and the Constitution of the Republic of Singapore seek to introduce a new legislative framework for psychoactive substances and increase the penalties for the possession of certain quantities of more dangerous and harmful controlled drugs. In so far as it concerns the reporting duty of medical practitioners, i.e. that they are required to report if they believe or has reasonable grounds to suspect that their client is a drug addict, this provision has remained unchanged.

New Legislative Framework for Psychoactive Substances

New psychoactive substances (“NPS“) are defined by the United Nations Office on Drugs and Crime (UNODC) as substances of abuse which are not controlled by international drug control conventions but which may pose a public health threat. Under the existing law, NPS are listed as controlled drugs in the First Schedule of the MDA (“First Schedule“). The listing is based on their chemical structure. New forms of NPS are temporarily listed in the Fifth Schedule of the MDA (“Fifth Schedule“) for up to 12 months, during which time the Central Narcotics Bureau (“CNB“) officers are empowered to seize these so as to restrict their circulation while scientific studies and industry consultations are being conducted to determine their legitimate uses. If these substances are found not to have legitimate uses, they will then be listed in the First Schedule as controlled drugs.

In this current set-up, the authorities cannot prosecute traffickers and abusers who are quick to produce or switch to new forms of psychoactive substances during the interim period, i.e. from the time a new form of psychoactive substance is first detected and listed in the Fifth Schedule until it is classified as a controlled drug and listed in the First Schedule.

New legislative framework introduced by the MDA Bill

To address this gap, the MDA Bill introduces a new legislative framework to control psychoactive substances based on their capacity to produce a psychoactive effect, rather than on their specific chemical structure. The MDA Bill proposes to criminalise the trafficking, manufacture, importing, exporting, possession, and consumption of psychoactive substances, thereby allowing CNB officers to seize such substances that are not yet scheduled as controlled drugs, and prosecute offenders.

MDA Bill defines a psychoactive substance as a substance or product that has the “capacity to have a psychoactive effect on an individual if the individual smokes, administers to himself or herself or otherwise consumes, the substance or product”. Psychoactive effect means the “stimulation or depression, whether directly or indirectly, of an individual’s central nervous system, affecting the individual’s mental functioning or emotional state”.

The new legislative framework will not apply to excluded substances or psychoactive substances that have legitimate uses, such as alcohol, tobacco and food additives.

Enhanced Penalties for Possession of Large Quantities of More Dangerous and Harmful Controlled Drugs

 It has been observed that syndicates are willing to deal in larger quantities of controlled drugs in each transaction, resulting in greater potential harm. In order to have a more deterrent effect, the MDA Bill proposes increased punishments, including caning, for the possession of large quantities of certain controlled drugs that are deemed to be more dangerous and harmful. These include morphine, diamorphine, opium, cocaine, cannabis, cannabis resin, cannabis mixture and methamphetamine.

Click on the following links for more information:

CONTACTS

Co-Head, Medical, Healthcare & Life Sciences
Co-Head, China-Related Investment Dispute Resolution
Chairperson, Rajah & Tann Foundation
+65 6232 0416
China, Singapore,
Regional Head, Mergers & Acquisitions
Co-Head, Medical, Healthcare & Life Sciences
Partner, Rajah & Tann Singapore
Partner, Christopher & Lee Ong (Malaysia)
Executive Committee Member, Rajah & Tann LCT Lawyers (Vietnam)
+65 6232 0606
Malaysia, Singapore, Vietnam,

Country

EXPERTISE

Share

Rajah & Tann Asia is a network of legal practices based in Asia.

Member firms are independently constituted and regulated in accordance with relevant local legal requirements. Services provided by a member firm are governed by the terms of engagement between the member firm and the client.

This website is solely intended to provide general information and does not provide any advice or create any relationship, whether legally binding or otherwise. Rajah & Tann Asia and its member firms do not accept, and fully disclaim, responsibility for any loss or damage which may result from accessing or relying on this website.

© 2024 Rajah & Tann Singapore LLP. All rights reserved. Rajah & Tann Singapore LLP (UEN T08LL0005E) is registered in Singapore under the Limited Liability Partnerships Act (Chapter 163A) with limited liability.